California State Teachers Retirement System Sells 699 Shares of Repligen Co. (NASDAQ:RGEN)

California State Teachers Retirement System lowered its stake in Repligen Co. (NASDAQ:RGENFree Report) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 82,357 shares of the biotechnology company’s stock after selling 699 shares during the quarter. California State Teachers Retirement System owned approximately 0.15% of Repligen worth $14,808,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in RGEN. Norges Bank bought a new position in Repligen in the 4th quarter worth about $48,208,000. Artemis Investment Management LLP bought a new stake in shares of Repligen during the 4th quarter valued at about $22,552,000. American Century Companies Inc. boosted its position in shares of Repligen by 97.5% during the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after acquiring an additional 107,570 shares during the last quarter. Comerica Bank boosted its position in shares of Repligen by 1,259.1% during the 3rd quarter. Comerica Bank now owns 115,929 shares of the biotechnology company’s stock valued at $18,434,000 after acquiring an additional 107,399 shares during the last quarter. Finally, Bamco Inc. NY boosted its position in shares of Repligen by 27.8% during the 3rd quarter. Bamco Inc. NY now owns 458,784 shares of the biotechnology company’s stock valued at $72,951,000 after acquiring an additional 99,763 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RGEN. Stifel Nicolaus lifted their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. JPMorgan Chase & Co. dropped their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Finally, KeyCorp lifted their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Check Out Our Latest Analysis on RGEN

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $145.78 on Friday. The stock has a market cap of $8.15 billion, a price-to-earnings ratio of 583.14, a P/E/G ratio of 4.96 and a beta of 1.04. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The stock’s 50-day moving average is $164.74 and its 200 day moving average is $177.15.

Repligen (NASDAQ:RGENGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. Repligen’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same period last year, the firm earned $0.64 earnings per share. On average, sell-side analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Repligen Company Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.